Security
ENDRA Life Sciences Inc. Common Stock · NDRA
NDRANASDAQCommon stockCurrentCIK 1681682Updated Nov 11, 2026
Name history
Endra Inc. · through Sep 21, 2016
NDRA price & chart
Loading TradingView…
NASDAQ:NDRA on TradingView ↗About the company
Inc. ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS® is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. Our press releases and financial and other material information are routinely posted to and accessible on the Investors section of our website, www.endrainc.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
425 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
425 filing
Other Events
Items 8.01
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,964,108Source | 8,379,110Source | 7,942,205Source | 2,807,672Source | 10,442,529Source | 3,438,182Source | 3,170,598Source | 5,060,701Source | 3,853,797Source | 4,452,362Source | 6,754,146Source | 9,274,147Source |
| Property, Plant and Equipment, NetUSD | 52,633Source | 80,281Source | 43,538Source | 63,419Source | 91,777Source | 33,024Source | 72,775Source | 111,470Source | 42,516Source | 69,281Source | 111,782Source | 235,655Source |
| Current assets: | ||||||||||||
| Inventory, NetUSD | 0Source | 2,711,923Source | — | 0Source | 2,711,923Source | — | 0Source | 2,711,923Source | 0Source | 0Source | 2,622,865Source | 2,644,717Source |
| Assets, CurrentUSD | 1,048,709Source | 4,962,307Source | 5,587,010Source | 1,852,884Source | 6,713,474Source | 536,666Source | 2,180,206Source | 1,270,522Source | 967,969Source | 3,433,665Source | 3,032,812Source | 8,526,690Source |
| Operating Lease, Right-of-Use AssetUSD | 491,363Source | 229,771Source | 400,717Source | 519,966Source | 272,284Source | 431,725Source | 546,216Source | 313,715Source | 461,949Source | 578,013Source | 354,091Source | 505,816Source |
| Other Assets, NoncurrentUSD | 5,986Source | — | 5,986Source | — | — | 5,986Source | — | — | 5,986Source | — | — | 5,986Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 1,792,728Source | 1,774,424Source | 1,632,514Source | 1,334,521Source | 1,448,588Source | 1,651,297Source | 1,417,713Source | 1,362,529Source | 1,593,677Source | 1,891,996Source | 1,095,157Source | 2,069,643Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 77Source | 53Source | 148Source | 74Source | 7,244Source | 122Source | 55Source | 1,092Source | 116Source | 53Source | 1,039Source | 317Source |
| Additional Paid in CapitalUSD | 107,467,603Source | 105,893,728Source | 117,999,522Source | 107,173,418Source | 105,921,675Source | 113,563,705Source | 106,227,259Source | 98,402,631Source | 112,725,513Source | 105,998,412Source | 97,582,868Source | 89,068,015Source |
| Retained Earnings (Accumulated Deficit)USD | -107,296,300Source | -99,289,095Source | -111,616,998Source | -105,700,341Source | -96,935,005Source | -111,776,942Source | -104,474,429Source | -94,705,852Source | -110,465,509Source | -103,438,099Source | -91,930,152Source | -81,869,902Source |
| Stockholders' Equity Attributable to ParentUSD | 171,380Source | 6,604,686Source | 6,309,691Source | 1,473,151Source | 8,993,941Source | 1,786,885Source | 1,752,885Source | 3,698,172Source | 2,260,120Source | 2,560,366Source | 5,658,989Source | 7,204,504Source |
| Liabilities and EquityUSD | 1,964,108Source | 8,379,110Source | 7,942,205Source | 2,807,672Source | 10,442,529Source | 3,438,182Source | 3,170,598Source | 5,060,701Source | 3,853,797Source | 4,452,362Source | 6,754,146Source | 9,274,147Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 800,307Source | 814,045Source | 786,578Source | 576,637Source | 1,350,167Source | 835,440Source | 565,785Source | 1,216,704Source | 750,956Source | 605,230Source | 903,095Source | 1,703,724Source |
| Operating Lease, Liability, CurrentUSD | 128,791Source | 187,339Source | 138,644Source | 128,218Source | 182,733Source | 133,953Source | 126,097Source | 178,239Source | 129,378Source | 96,937Source | 173,857Source | 152,228Source |
| Accounts Payable, CurrentUSD | 252,491Source | 279,417Source | 464,976Source | 281,992Source | 300,356Source | 456,837Source | 223,595Source | 521,577Source | 382,970Source | 269,683Source | 360,401Source | 613,961Source |
| Operating Lease, Liability, NoncurrentUSD | 396,537Source | 49,823Source | 290,630Source | 429,274Source | 98,421Source | 327,253Source | 461,206Source | 145,825Source | 362,974Source | 487,482Source | 192,062Source | 365,919Source |
| Additional Financial Items | ||||||||||||
| Long-term DebtUSD | — | — | — | — | — | — | — | 0Source | — | 0Source | 0Source | 365,919Source |
| Cash and Cash Equivalents, at Carrying Value | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
| Preferred Stock, Value, Issued | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Accrued Liabilities, Current | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | 159,944Source | -1,225,912Source | — | -1,036,330Source | — | -11,507,947Source | — | 13,179,092Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 9,492Source | 13,786Source | 44,045Source | 46,489Source | 123,726Source | 96,661Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 574,451Source | 83,046Source | 329,409Source | 571,924Source | 996,430Source | 1,199,838Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | 0Source | — | -235,731Source | 116,193Source | 1,360,139Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,119,650Source | -1,293,129Source | -5,182,558Source | -7,400,547Source | -9,548,775Source | -12,769,371Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 450,000Source | -17,280Source | -3,017,280Source | -12,796Source | -24,721Source | -202,577Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 17,280Source | 17,280Source | 16,000Source | 33,884Source | 202,577Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 263,747Source | 145,803Source | 5,732,723Source | 7,808,917Source | 7,518,305Source | 8,399,512Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 794,036Source | 4,745,187Source | 5,539,946Source | 1,808,574Source | 356,462Source | 2,064,874Source | 762,365Source | 3,229,480Source | 2,833,907Source | 4,889,098Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 12,051Source | 14,855Source | 55,848Source | 31,910Source | 44,985Source | 59,113Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | 0Source | — | 0Source | 0Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | 186,287Source | — | — | — |
| DepreciationUSD | — | — | 10,786Source | 11,496Source | — | — | 9,492Source | 13,786Source | 44,045Source | 46,489Source | 123,726Source | 96,661Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 3,071,252Source | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 893,305Source | 631,413Source | 1,243,778Source | 851,195Source | 1,393,060Source | 871,606Source | 3,723,635Source | 7,055,814Source | 4,696,486Source | 5,174,215Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | 0Source | — | 0Source | — | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,595,959Source | -2,354,090Source | 159,944Source | -1,225,912Source | -1,311,433Source | -1,036,330Source | -7,027,410Source | -11,507,947Source | -10,060,250Source | -13,179,092Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -13,179,092Source |
| Nonoperating Income (Expense)USD | — | — | -225,256Source | -845,076Source | 1,643,200Source | 75,178Source | 862,315Source | 432,952Source | -1,264,309Source | — | 460,485Source | -21,533Source |
| Operating ExpensesUSD | — | — | 1,370,703Source | 1,509,014Source | 1,483,256Source | 1,301,090Source | 2,173,748Source | 1,469,282Source | 5,763,101Source | 10,817,147Source | 10,520,735Source | 13,157,559Source |
| Other Nonoperating Income (Expense)USD | — | — | 42,018Source | 65,528Source | — | 13,066Source | — | 24,390Source | — | -690,800Source | 460,485Source | -21,533Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 263,747Source | 145,803Source | 1,218,241Source | 1,148,470Source | 6,483,393Source | 8,399,512Source |
| Repayments of Long-term Debt | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Derivative, Gain (Loss) on Derivative, Net | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Gain (Loss) on Disposition of Assets | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -1,370,703Source | -1,509,014Source | -1,483,256Source | -1,301,090Source | -2,173,748Source | -1,469,282Source | -5,763,101Source | -10,817,147Source | -10,520,735Source | -13,157,559Source |
| Other Nonoperating Income (Expense)USD | — | — | 42,018Source | 65,528Source | — | 13,066Source | — | 24,390Source | — | -690,800Source | 460,485Source | -21,533Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -1,595,959Source | -2,354,090Source | 159,944Source | -1,225,912Source | -1,311,433Source | -1,036,330Source | -7,027,410Source | -11,507,947Source | -10,060,250Source | -13,179,092Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | 0Source | — | 0Source | — | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,595,959Source | -2,354,090Source | 159,944Source | -1,225,912Source | -1,311,433Source | -1,036,330Source | -7,027,410Source | -11,507,947Source | -10,060,250Source | -13,179,092Source |
| Earnings Per Share, BasicUSD per share | — | — | -2.1Source | -9.54Source | 0.12Source | -1.71Source | -1.09Source | -1.86Source | -8.93Source | — | — | -4.56Source |
| Earnings Per Share, DilutedUSD per share | — | — | -2.1Source | -9.54Source | 0.06Source | -1.71Source | -1.09Source | -1.86Source | -8.93Source | -56.94Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 761,218Source | 246,816Source | 1,324,046Source | 717,107Source | 1,199,586Source | 557,582Source | 787,020Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 761,218Source | 246,816Source | 2,475,261Source | 717,107Source | 1,199,586Source | 557,582Source | 787,020Source | 202,106Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | 13,786Source | — | 46,489Source | 123,726Source | — |
| General and Administrative ExpenseUSD | — | — | 893,305Source | 631,413Source | 1,243,778Source | 851,195Source | 1,393,060Source | 871,606Source | 3,723,635Source | 7,055,814Source | 4,696,486Source | 5,174,215Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -6,465,510Source | -10,434,147Source | -8,403,400Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -13,179,092Source |
| Nonoperating Income (Expense)USD | — | — | -225,256Source | -845,076Source | 1,643,200Source | 75,178Source | 862,315Source | 432,952Source | -1,264,309Source | — | 460,485Source | -21,533Source |
| Operating ExpensesUSD | — | — | 1,370,703Source | 1,509,014Source | 1,483,256Source | 1,301,090Source | 2,173,748Source | 1,469,282Source | 5,763,101Source | 10,817,147Source | 10,520,735Source | 13,157,559Source |
| Other IncomeUSD | — | — | — | — | -45Source | 13,066Source | 351Source | 24,390Source | 71,224Source | 108,484Source | — | — |
| Research and Development ExpenseUSD | — | — | 432,113Source | 794,444Source | 233,665Source | 381,061Source | 776,410Source | 528,685Source | 1,849,996Source | 3,190,293Source | 5,003,695Source | 6,554,194Source |
| Selling and Marketing ExpenseUSD | — | — | 45,285Source | 83,157Source | 5,813Source | 68,834Source | 4,278Source | 68,991Source | 189,470Source | 571,040Source | 820,554Source | 1,429,150Source |
Offerings
Registration 333-299256
Filing attachments
ndra-ex4_5.htm · S-4 · 2026-10-02
Exhibit 4.5 AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT This AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT (this “Amendment”) is entered into as of October 1, 2026, by and between ENDRA Life Sciences Inc., a Delaware corporation (the “Company”), and such holder identified on the signature page hereto (the “Holder”). Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings set forth in the Original Warrant (as defined below). From and after the …
Read attachment ↗ndra-ex4_6.htm · S-4 · 2026-10-02
Exhibit 4.6 AMENDMENT NO. 1 TO PRE-FUNDED COMMON STOCK PURCHASE WARRANT This AMENDMENT NO. 1 TO PRE-FUNDED COMMON STOCK PURCHASE WARRANT (this “Amendment”) is entered into as of October 1, 2026, by and between ENDRA Life Sciences Inc., a Delaware corporation (the “Company”), and such holder identified on the signature page hereto (the “Holder”). Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings set forth in the Original Warrant (as defined below…
Read attachment ↗ndra-ex99_1.htm · S-4 · 2026-10-02
Exhibit 99.1 2026 Update on the Estimation of Natural Gas Reserves, Including Helium, and Associated Economics of Tetra4’s Interest in the Virginia Gas Field in the Free State of the Republic of South Africa (As of February 28, 2026) Prepared For: Renergen Limited By: Sproule ERCE Digital Report Notification This report has been prepared in a fully digital, auditable, and legally compliant format using a PDF/A standard (ISO 19005-1, 2 or 3). Sproule ERCE profess…
Read attachment ↗ndra-ex99_2.htm · S-4 · 2026-10-02
Exhibit 99.2 2025 Update on the Estimation of Natural Gas Reserves, Including Helium, and Associated Economics of Tetra4’s Interest in the Virginia Gas Field in the Free State of the Republic of South Africa (As of February 28, 2025) Prepared For: Renergen Limited By: Sproule ERCE Digital Report Notification This report has been prepared in a fully digital, auditable, and legally compliant format using a PDF/A standard (ISO 19005-1, 2 or 3). Sproule ERCE profess…
Read attachment ↗ea030701101ex4-1.htm · 425 · 2026-10-01
Exhibit 4.1 AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT This AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT (this “ Amendment ”) is entered into as of October 1, 2026, by and between ENDRA Life Sciences Inc., a Delaware corporation (the “ Company ”), and such holder identified on the signature page hereto (the “ Holder ”). Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings set forth in the Original Warrant (as defined below). From and afte…
Read attachment ↗ea030701101ex4-2.htm · 425 · 2026-10-01
Exhibit 4.2 AMENDMENT NO. 1 TO PRE-FUNDED COMMON STOCK PURCHASE WARRANT This AMENDMENT NO. 1 TO PRE-FUNDED COMMON STOCK PURCHASE WARRANT (this “ Amendment ”) is entered into as of October 1, 2026, by and between ENDRA Life Sciences Inc., a Delaware corporation (the “ Company ”), and such holder identified on the signature page hereto (the “ Holder ”). Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings set forth in the Original Warrant (as defined…
Read attachment ↗